EGFR and neoplasm: Tumor cells will exocytose ANGPTL4 and SEMA3C molecules to help stromal cells achieve distant metastasis and weaken the anti-tumor immune function of immune cells, creating a microenvironment more suitable for the survival of malignant tumor cells, and also changing the function of immune cells to exocytose EREG to activate the EGFR pathway in tumor cells, making LUAD resistant to TKI drug.